- Lupin has launched a new subsidiary, Lupin Manufacturing Solutions (LMS), to enter the CDMO business.
- Abdelaziz Toumi has been appointed as the CEO of LMS, bringing over two decades of industry experience.
Lupin has announced the formation of a new subsidiary, Lupin Manufacturing Solutions (LMS), marking its entry into the contract development and manufacturing organisation (CDMO) sector. On Monday, the company named Abdelaziz Toumi (Abdel) as the chief executive officer of LMS.
LMS will focus on the development, manufacture, and sale of active pharmaceutical ingredients (APIs). The new venture aims to build a robust CDMO business to serve global customers. Abdelaziz Toumi, with over two decades of experience in the biotech, pharma, and CDMO sectors, will lead LMS. His previous roles at Bayer, Merck, Catalent, Lonza, and KBI Biopharma highlight his expertise in driving growth, innovation, and operational excellence.
Abdel will be based in Switzerland but will spend significant time in India, overseeing the development and operations of LMS. Nilesh Gupta, Managing Director of Lupin, expressed confidence in Abdel’s leadership, stating, “We are delighted to welcome Abdel to our team. He brings a wealth of knowledge and experience in the API CDMO space and will be instrumental in establishing LMS as a trusted and preferred partner for our global customers.”
Lupin’s strategic move into the CDMO market reflects its commitment to expanding its capabilities and offering comprehensive solutions in pharmaceutical development and manufacturing. The establishment of LMS under Abdel’s leadership is expected to enhance Lupin’s global footprint and operational capacity.
Overview of outsourcing trends 
